1.12  -0.01 (-0.89%)		07-31 15:59
Open: 1.13 High: 1.13 Volume: 19,003		Pre. Close: 1.13 Low: 1.11 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	1.32	1-year :	1.34
Resists	First :	1.13	Second :	1.14
Pivot price	1.11
Supports	First :	1.1	Second :	0.91
MAs	MA(5) :	1.12	MA(20) :	1.11
	MA(100) :	0.9	MA(250) :	1.45
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	50	D(3) :	41.6
RSI	RSI(14): 60.8
52-week	High :	7.61	Low :	0.63

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ REUN ] has closed below upper band by 39.3%. Bollinger Bands are 90.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.12 - 1.13	1.13 - 1.13
Low:	1.1 - 1.11	1.11 - 1.12
Close:	1.11 - 1.12	1.12 - 1.13

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.

Tue, 01 Aug 2023
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement - GlobeNewswire

Fri, 14 Jul 2023
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement - Yahoo Finance

Thu, 13 Jul 2023
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement - GlobeNewswire

Fri, 02 Jun 2023
What's Going On With Reunion Neuroscience Stock Today - Yahoo Finance

Thu, 01 Jun 2023
Reunion Neuroscience Announces US$13.1 Million Take-Private - GlobeNewswire

Thu, 01 Jun 2023
MPM BioImpact to Acquire Reunion Neuroscience for $13.1 Million in All-Cash Deal - Green Market Report

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	12 (M)
Shares Float	3 (M)
Held by Insiders	34.3 (%)
Held by Institutions	50.6 (%)
Shares Short	115 (K)
Shares Short P.Month	179 (K)

EPS	-2.51
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.82
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-26.5 %
Return on Equity (ttm)	-86.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.2
Qtrly Earnings Growth	0 %
Operating Cash Flow	-28 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-0.45
PEG Ratio	0
Price to Book value	0.61
Price to Sales	0
Price to Cash Flow	-0.48

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.